Spanish journal wins lawsuit over COX-2 drug editorial

Meek, Colin
March 2004
CMAJ: Canadian Medical Association Journal;3/16/2004, Vol. 170 Issue 6, p940
Academic Journal
Reports on the decision of a Spanish court on a lawsuit filed by pharmaceutical firm Merck, Sharpe & Dohme against the editor and publisher of drug bulletin "Butlletí Groc" for publishing a June 2002 article "The So-Called Advantages of Celecoxib and Rofecoxib: Scientific Fraud." Overview of the article; Facts of the case; Arguments of the lawsuit respondent.


Related Articles

  • Drug company loses battle to stop article. Goldbeck-Wood, Sandra // BMJ: British Medical Journal (International Edition);12/13/97, Vol. 315 Issue 7122, p1563 

    Reports about the case of pharmacetical companies Merck Sharpe and Dohme (MSD) against `Nytt om Legemidler,' a Norwegian publication. Argument over publication of an article criticizing osteoporosis drug Fosamax; Basis of the injunction order sought by MSD; Statement released by Judge Stein...

  • Drug company fined for excessive hospitality. Sheldon, Tony // BMJ: British Medical Journal (International Edition);02/17/2001, Vol. 322 Issue 7283, p382 

    Reports that Merck Sharp and Dohme became the first pharmaceutical companies in the Netherlands to be prosecuted for excessively entertaining doctors in promotion of their drugs. How the were fined for their promotion of the antimigraine drug rizatriptan (Maxalt); Need for hospitality to be...

  • COX-2s and heart disease.  // GP: General Practitioner;1/27/2003, p2 

    Reports on the benefit of COX-2 inhibitors to patients with heart diseases as well as arthritis. Endothelial functions improved by the inhibitor celecobix; Other therapeutic uses of celecobix.

  • Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Klein, Thomas; Eltze, Manfrid; Grebe, Thomas; Hatzelmann, Armin; K�mhoff, Martin // Cardiovascular Research;Jul2007, Vol. 75 Issue 2, p390 

    Abstract: Objective : Celecoxib carries a smaller cardiovascular risk for myocardial infarction and hypertension than other cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drugs NSAIDs (�coxibs�) and may ameliorate endothelial dysfunction. We aimed to determine which...

  • Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus. L. Bolieva; F. Dzhioev; S. Kakabadze // Bulletin of Experimental Biology & Medicine;Jan2007, Vol. 143 Issue 1, p87 

    Abstract  The effects of nonsteroid antiinflammatory drugs (acetylsalicylic acid and celecoxib) on N-nitrosodiethylamine-induced carcinogenesis in the liver and esophagus were studied in rats. The inhibitory effect of celecoxib on carcinogenesis was more pronounced (in comparison with...

  • The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Kawashima, Masayuki; Fujikawa, Yosuke; Itonaga, Ichiro; Takita, Chikahiro; Tsumura, Hiroshi // Modern Rheumatology (Springer Science & Business Media B.V.);Apr2009, Vol. 19 Issue 2, p192 

    The inducible prostaglandin synthesis enzyme, cyclooxygenase-2 (COX-2), is involved in bone resorption and osteoclastogenesis, and acts indirectly through prostaglandin E2 (PG E2) produced by osteoblastic cells. This study was undertaken to investigate whether celecoxib (a selective COX-2...

  • COX-2 inhibitors: 'risk-inducing' effect at higher doses.  // Reactions Weekly;10/14/2006, Issue 1123, p5 

    The article discusses research being done on the risk-reducing effect of cyclooxygenase-2 inhibitors at higher doses. According to researchers from Australia, the overall risk of acute coronary syndromes (ACS) does not appear to increase with the use of celecoxib or rofecoxib, but the odds of...

  • Drug company sues Spanish bulletin over fraud claim. Gibson, Liza // BMJ: British Medical Journal (International Edition);1/24/2004, Vol. 328 Issue 7433, p188 

    Discusses the lawsuit by Merck Sharp & Dohme pharmaceutical company against Spain's independent drug bulletin "Butlletí Groc" for an article that claimed Merck committed scientific fraud in a trial of its cyclo-oxegenase inhibitor rofecoxib. Push by the company to have the bulletin retract...

  • Vioxx class action victory.  // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p63 

    The article discusses the court case wherein grandfather Graeme Peterson won over Merck Sharp & Dohme Ltd. (MSD) for claims of injury by arthritis drug Vioxx in Australia. The Federal Court rules that Peterson will be awarded 287,912 dollars plus interest. The court's decision pave the way for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics